Editor’s note: A recording of the event is embedded below.
After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.
advertisement
Featured Speakers
- Irena Melnikova, Ph.D., partner, Pfizer Ventures
- Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
- Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)
Get unlimited access to award-winning journalism and exclusive events.
Subscribe Log In
Previous article：
The biotech scorecard for Q3: 15 stock
Next article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
